Generate Biomedicines, Inc.
GENB- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0002100782
In the last 90 days, Generate Biomedicines, Inc. insiders filed 0 open-market purchases and 2 sales; 86 institutions reported holding it in 13F filings for Q2 2026, worth $1.69B in total; ARK Invest is the only superinvestor holding it.
Key figures
- Market capClose on Nov 11, 2026
- $1.73B
- Insider buysOpen market, last 90 days
- 0
- Insider sellsLast 90 days, $200.7K in total
- 2
- 13F holdersQ2 2026, +29 vs. previous quarter
- 86
- 13F valueReported value at the end of Q2 2026
- $1.69B
- Superinvestors holdingAt the end of Q2 2026
- 1
Price chart
Financials
See financial statementsFrom SEC filings, in USD.
- Revenue, Q2 FY2026
- $6.31M
- No comparable prior period
Short interest
See short dataFrom FINRA, settlement date Oct 30, 2026.
- Short interest
- 9.08M
- Shares sold short
- Change
- +154.1K
- +1.7% vs. previous
- Days to cover
- 8.87
- At average daily volume
Superinvestors holding GENB, Q2 2026
Go to the superinvestors tab1 superinvestor reports holding Generate Biomedicines, Inc. on Form 13F. Percentages are the stock's share of each portfolio.
ARK Invest
Cathie Wood
0.1%
Generate Biomedicines, Inc.'s share of the portfolio
- Shares
- 1,284,617
- Value
- $21.7M
Latest insider trades
See all insider tradesOpen-market purchases and sales by Generate Biomedicines, Inc. insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Nov 4, 2026 (view filing)4:05 PM ET | Oct 29 | 6 daysLate | Arnold FrancesDirector | SSale | −11.4K | $16.19 | −$184.7K | −4.9%220.1K after | 10b5-1 |
| Sep 3, 2026 (view filing)4:05 PM ET | Sep 1 | 2 days | Arnold FrancesDirector | SSale | −1.00K | $16.00 | −$16.0K | −0.4%231.5K after | 10b5-1 |
| Mar 6, 2026 (view filing) | Mar 4 | 2 days | Nally MichaelChief Executive Officer | PPurchase | +20.0K | $12.00 | +$240.0K | +3.6%572.7K after | |
| Mar 2, 2026 (view filing)5:52 PM ET | Mar 2 | Same day | Afeyan Noubar and 7 othersDirector, 10% Owner | PPurchase | +4.69M | $16.00 | +$75.0M | New position1.56M after | 3 lotsDuplicate filing |
| Mar 2, 2026 (view filing)5:42 PM ET | Mar 2 | Same day | Afeyan Noubar and 6 othersDirector, 10% Owner | PPurchase | +4.69M | $16.00 | +$75.0M | New position1.56M after | 3 lots |
| Mar 2, 2026 (view filing) | Mar 2 | Same day | Grous BethChief People Officer | PPurchase | +300 | $16.00 | +$4.80K | New position300 after | |
| Mar 2, 2026 (view filing) | Mar 2 | Same day | Silvers JasonPresident & CFO | PPurchase | +2.00K | $16.00 | +$32.0K | New position1.00K after | 3 lots |
| Mar 2, 2026 (view filing) | Mar 2 | Same day | Mendillo Jane LDirector | PPurchase | +1.50K | $16.00 | +$24.0K | New position1.50K after |
Top 10 13F holders, Q2 2026
See all 86 holdersThe largest institutional positions in Generate Biomedicines, Inc. at the end of Q2 2026; share changes are against Q1 2026.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Flagship Pioneering Inc. | 62,673,117 | $1.06B | 68.66% | 00.0% | Unchanged |
| FMR LLC | 5,221,599 | $88.1M | 0.00% | +1,004,075+23.8% | Added |
| Capital World Investors | 4,215,632 | $71.1M | 0.01% | +211,483+5.3% | Added |
| Braidwell LP | 3,283,844 | $55.4M | 2.05% | −309,155−8.6% | Reduced |
| Price T Rowe Associates Inc | 2,156,627 | $36.4M | 0.00% | +46,994+2.2% | Added |
| Norges Bank | 2,094,616 | $35.3M | 0.00% | +2,094,616 | New |
| ARCH Venture Management, LLC | 1,944,426 | $32.8M | 2.98% | 00.0% | Unchanged |
| HarbourVest Partners LLC | 1,722,210 | $29.1M | 17.09% | 00.0% | Unchanged |
| BlackRock, Inc. | 1,659,966 | $28.0M | 0.00% | +1,659,966 | New |
| Baker Bros. Advisors LP | 1,423,602 | $24.0M | 0.12% | 00.0% | Unchanged |
Holders of 5% or more of GENB
See all 3 holders and filingsHolders whose latest Schedule 13D or 13G filing reports 5% or more of Generate Biomedicines, Inc..
| Holder | Latest form | Stake | Change | First filed | Latest filing | Filing |
|---|---|---|---|---|---|---|
| Flagship Pioneering Inc. | 13G | 48.90%62.7M shares | New | May 15, 20261 filing | May 15, 2026 | SEC |
| FMR LLC | 13G | 5.60%7.19M shares | New | Nov 5, 20261 filing | Nov 5, 2026 | SEC |
| Nally Michael | 13G | 5.20%6.92M shares | New | May 15, 20261 filing | May 15, 2026 | SEC |